stockrow
Friday 6 November 2026
Export ORGS’s income statement to Excel — free account
Orgenesis Inc.
ORGS Healthcare Biotechnology
Orgenesis Inc.’s revenue for fiscal 2024 (year ended December 2024) was $1.0 million, up 95.3% from fiscal 2023.
- Revenue
- +82.4%
- EPS
- −104.5%
- Free cash flow
- −317.9%
Quarter to December 2024, against a year earlier
0.35
0.05
−12.50%
Follow ORGS
Alert me
| Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Nov '18 | Dec '17 | Nov '17 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
3 | 1 | 3 | 3 | 5 | — | — | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 2.00 | 5.01 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
7.69 | 28.71 | 1.37 | 1.97 | 12.54 | 19.01 | 3.05 | 5.60 | 6.31 | 5.40 |
Altman Z-Score |
(352.42) | (29.89) | (0.96) | (0.64) | (2.73) | (1.11) | (0.74) | (0.31) | 11.85 | (1.50) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 24.18 | 20.69 |
Altman Z″-Score (non-manufacturers) |
(868.26) | (70.52) | (2.41) | (4.63) | (6.92) | (2.13) | (2.85) | (2.22) | (7.90) | (6.51) |
Beneish M-Score |
— | — | (1.20) | — | — | — | — | (0.54) | — | (4.52) |
P/Operating CF |
(3.79) | (30.31) | (4.57) | (28.37) | (2.12) | (27.40) | (14.60) | (15.49) | (32.61) | (27.90) |
P/B ratio |
0.00 | 0.00 | 1.69 | 1.81 | 1.82 | 12.20 | 2.34 | 3.01 | 3.83 | 3.28 |
Price to Tangible BV |
0.00 | 0.00 | 4.40 | 3.80 | 3.10 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
23.15 | 67.98 | 1.69 | 2.10 | 8.07 | 22.19 | 2.54 | 4.81 | 6.81 | 5.90 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(1.40) | (2.43) | (2.44) | (2.78) | (0.79) | (6.54) | (3.11) | (5.25) | 18.98 | 16.44 |
EV/FCF |
(1.38) | (2.13) | (1.64) | (2.15) | (0.78) | (3.42) | (2.28) | (3.96) | 26.10 | 22.60 |
Quick Ratio |
0.03 | 0.12 | 2.67 | 1.39 | 3.00 | 0.06 | 1.47 | 1.61 | 0.34 | 0.34 |
Current Ratio |
0.03 | 0.25 | 2.91 | 1.68 | 3.08 | 1.85 | 1.64 | 1.77 | 0.43 | 0.43 |
Net Debt/EBITDA |
(0.42) | (0.40) | (1.42) | (0.32) | 0.36 | (0.68) | 0.75 | 1.06 | (0.56) | (0.50) |
Debt/Assets |
1,235.53% | 153.18% | 19.73% | 18.01% | 14.65% | 14.00% | 6.13% | 4.94% | 19.29% | 19.58% |
Debt/Equity |
(0.44) | (1.06) | 0.62 | 0.28 | 0.22 | 2.13 | 0.17 | 0.13 | 0.54 | 0.55 |
Asset Turnover |
0.13 | 0.01 | 0.48 | 0.52 | 0.09 | 0.05 | 0.27 | 0.32 | 0.25 | 0.28 |
Operating CF/Net income |
0.35 | 0.27 | 1.67 | 1.49 | (12.45) | 0.47 | 0.76 | 0.86 | 0.31 | 0.31 |
Capex/Depreciation |
(0.13) | (1.34) | (6.15) | (4.22) | (1.06) | (3.17) | (2.11) | (2.12) | 0.00 | (0.38) |
Interest Coverage |
(8.82) | (21.46) | (5.13) | (13.00) | (90.27) | (26.07) | (5.37) | (4.70) | — | (4.59) |
| 164.62% | (1,368.97%) | (43.98%) | (39.52%) | 21.32% | (171.90%) | (79.78%) | (85.53%) | (87.57%) | (92.92%) | |
| (605.73%) | (104.97%) | (19.75%) | (26.25%) | 7.37% | (33.92%) | (29.60%) | (31.72%) | (31.02%) | (33.72%) | |
ROIC |
0.00% | 0.00% | (15.55%) | (24.17%) | (322.83%) | (74.42%) | (64.80%) | (57.52%) | 0.00% | (38.12%) |
Return on Tangible Assets |
188.28% | 509.96% | (27.96%) | (87.36%) | 17.01% | (73.83%) | (94.62%) | (73.01%) | 273.91% | 273.91% |
Average Days of Receivables |
14.11 | 376.02 | 366.60 | 158.47 | 155.22 | 190.50 | 182.74 | 218.98 | 79.95 | 79.95 |
Research and Development Expense of Revenue |
929.66% | 2,004.34% | 60.88% | 100.75% | 1,089.69% | 346.06% | 38.50% | 34.65% | 23.47% | 24.56% |
Selling, General and Administrative Expense of Revenue |
1,432.08% | 6,629.06% | 43.27% | 41.43% | 247.95% | 293.69% | 89.17% | 87.39% | 91.08% | 91.08% |
Intangible Assets out of Total Assets |
0.00 | 0.59 | 0.20 | 0.34 | 0.28 | 0.09 | 0.43 | 0.42 | 0.65 | 0.65 |
Share Based Compensation of Revenue |
308.60% | 87.36% | 2.73% | 4.92% | 260.00% | 146.14% | 24.86% | 23.39% | 0.00% | 33.34% |
Graham Net Nets |
(4.79) | (2.07) | (0.32) | 0.07 | 0.26 | (0.11) | (0.30) | (0.19) | (0.34) | (0.40) |
Graham Number |
48.05 | 55.06 | 0.00 | 0.00 | 111.89 | 28.28 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(608.99%) | (403.62%) | (24.74%) | (25.69%) | 49.99% | 19.96% | (35.17%) | (22.92%) | (30.21%) | (35.31%) |
Free Cash Flow Yield |
(217.87%) | (111.28%) | (75.41%) | (49.68%) | (82.93%) | (34.09%) | (36.51%) | (21.71%) | 4.14% | 4.83% |
Revenue per Share |
0.25 | 0.18 | 14.35 | 14.63 | 3.59 | 2.45 | 15.33 | 13.95 | 1.04 | 10.42 |
Operating CF per Share |
(4.06) | (5.11) | (9.93) | (11.07) | (36.61) | (8.31) | (12.53) | (11.73) | (0.40) | (3.96) |
Capex per Share |
(0.06) | (0.72) | (4.85) | (3.24) | (0.71) | (7.57) | (4.55) | (4.15) | 0.00 | (1.01) |
Free Cash Flow per Share |
(4.12) | (5.84) | (14.78) | (14.31) | (37.32) | (15.89) | (17.09) | (15.88) | (0.40) | (4.97) |
Cash per Share |
0.16 | 0.51 | 2.54 | 2.46 | 21.37 | 0.36 | 11.22 | 12.30 | 0.36 | 3.64 |
Shareholders Equity per Share |
(8.91) | (7.23) | 11.58 | 15.91 | 24.73 | 3.82 | 20.00 | 21.42 | 1.46 | 14.59 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(8.91) | (7.23) | 11.58 | 15.91 | 24.73 | 3.82 | 20.00 | 21.42 | 1.46 | 14.59 |
Free Cash Flow |
(17.34) | (16.93) | (37.09) | (34.73) | (79.56) | (25.27) | (22.85) | (21.24) | (3.83) | (4.81) |
Working Capital |
(26.16) | (12.33) | 30.41 | 10.39 | 33.79 | 35.91 | 10.90 | 13.15 | (9.62) | (9.62) |
Capital Expenditures |
(0.26) | (2.10) | (12.17) | (7.87) | (1.52) | (12.05) | (6.09) | (5.56) | (0.97) | (0.97) |
Net Current Asset Value |
(38.12) | (31.46) | (15.54) | 4.55 | 25.12 | (8.07) | (19.07) | (16.50) | (14.85) | (18.45) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.25 | 3.95 | 0.34 | 0.22 | 0.20 | 3.09 | 0.30 | 0.30 | 0.00 | 0.10 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
3.61 | 1.06 | 0.09 | 0.18 | 0.47 | 1.65 | 0.23 | 0.22 | 0.51 | 0.51 |
Cash ROIC |
86.03% | (607.57%) | (69.49%) | (62.71%) | (72.54%) | (128.92%) | (49.37%) | (43.49%) | (15.13%) | (18.89%) |
Accounts Receivable Turnover |
3.53 | 0.03 | 1.40 | 3.80 | 2.89 | 0.63 | 1.91 | 2.78 | 4.57 | 4.64 |
Accounts Payable Turnover |
0.20 | 1.14 | 1.06 | 5.28 | 11.83 | 2.77 | 2.87 | 2.80 | 2.18 | 1.61 |
Inventory Turnover |
0.00 | 81.23 | 43.13 | 241.87 | 523.28 | 15.61 | 7.09 | 8.80 | 11.79 | 12.10 |
Average Days of Payables |
2,484.39 | 384.20 | 314.94 | 52.17 | 37.59 | 144.53 | 138.88 | 128.28 | 167.13 | 209.87 |
Days of Inventory on Hand |
0.00 | 1.98 | 8.53 | 1.18 | 0.80 | 3.54 | 50.30 | 58.54 | 30.96 | 38.88 |
Average Receivables |
0.29 | 18.36 | 25.80 | 9.33 | 2.64 | 6.15 | 10.73 | 6.70 | 2.21 | 2.17 |
Average Payables |
9.85 | 5.51 | 4.83 | 6.94 | 7.10 | 5.07 | 4.19 | 3.86 | 3.91 | 4.23 |
Average Inventory |
— | 0.08 | 0.12 | 0.15 | 0.16 | 0.90 | 1.70 | 1.23 | 0.73 | 0.56 |
Average Assets |
7.95 | 52.74 | 75.38 | 68.76 | 85.09 | 83.19 | 74.66 | 57.66 | 39.87 | 36.68 |
Average Common Equity |
(29.26) | 4.04 | 33.85 | 45.68 | 29.40 | 16.41 | 27.70 | 21.39 | 14.12 | 13.31 |
Columns are period end dates · fundamentals updated 2 Nov 2026